CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Merck will record a pre-tax charge relating to the upfront payment of $588 million
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Merck has also decided to end the favezelimab clinical development program
Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Subscribe To Our Newsletter & Stay Updated